13F Filings History of BRAIDWELL LP

Latest 13F report: Q1 2026 - 15 May 2026
Value $: $2,997,744,331
Signature - Title: Ken Joseph - Chief Compliance Officer
Location: Stamford, CT
Summary: This page shows a list of all the recent 13F filings made by BRAIDWELL LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. BRAIDWELL LP reported 88 stock holdings with total value $2,997,744,331 as of Q1 2026. Top holdings included CAI, GUARDANT HEALTH INC, REPLIGEN CORP, NEOGENOMICS INC, and NBIX.

Follow Filing Activity

Follow BRAIDWELL LP and return when a new 13F portfolio filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Holdings Value

Key facts

BRAIDWELL LP reports institutional holdings through Form 13F filings.
Latest reported quarter: Q1 2026.
Latest reported holdings value: $2,997,744,331.

Change

Most recent filing was accepted on 15 May 2026, 16:08.
Reported value moved from $3,126,999,740 to $2,997,744,331.

Research use

This gives a plain-language read of holdings direction before you open full quarter tables.
Use the filing links below to verify the exact SEC source document.

Evidence

Backed by Form 13F

Portfolio holdings and changes are grounded in SEC Form 13F filings.

See Original Filing

Quarter	Holdings	Value $	Bought	Sold	Net	Top Holdings	Form Type	Filing Time
Q1 2026	88	$2,997,744,331	+$753,141,357	-$862,875,282	-$109,733,925	CAI, GUARDANT HEALTH INC, REPLIGEN CORP, NEOGENOMICS INC, NBIX	13F-HR	15 May 2026, 16:08
Q4 2025	73	$3,126,999,740	+$722,490,100	-$1,480,181,233	-$757,691,133	CAI, GUARDANT HEALTH INC, EWTX, REPLIGEN CORP, NBIX	13F-HR	17 Feb 2026, 17:12
Q3 2025	73	$3,370,348,920	+$737,465,023	-$575,050,783	+$162,414,240	GUARDANT HEALTH INC, CAI, NOVOCURE LTD, XENE, CGON	13F-HR	14 Nov 2025, 16:07
Q2 2025	55	$2,923,924,032	+$499,741,109	-$570,956,679	-$71,215,570	GUARDANT HEALTH INC, CAI, NBIX, NOVOCURE LTD, XENE	13F-HR	14 Aug 2025, 16:34
Q1 2025	64	$2,844,802,567	+$846,348,550	-$1,118,782,305	-$272,433,755	GUARDANT HEALTH INC, NOVOCURE LTD, NBIX, LEGN, REPLIGEN CORP	13F-HR	15 May 2025, 16:34
Q4 2024	73	$3,372,652,431	+$584,985,822	-$597,705,270	-$12,719,448	GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NBIX, REPLIGEN CORP	13F-HR	14 Feb 2025, 16:18
Q3 2024	81	$3,527,985,574	+$699,942,636	-$551,185,675	+$148,756,961	GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, CGON, NUVASIVE INC	13F-HR	14 Nov 2024, 16:22
Q2 2024	75	$3,187,767,909	+$925,413,405	-$688,113,088	+$237,300,317	GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NUVASIVE INC, NBIX	13F-HR	14 Aug 2024, 16:29
Q1 2024	70	$3,102,773,641	+$917,098,241	-$612,267,221	+$304,831,020	GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, EXACT SCIENCES CORP, NOVOCURE LTD, APGE	13F-HR	15 May 2024, 16:26
Q4 2023	72	$2,722,670,757	+$374,961,295	-$1,014,613,338	-$639,652,043	GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NOVOCURE LTD	13F-HR	14 Feb 2024, 16:37
Q3 2023	85	$3,164,360,709	+$710,756,067	-$423,382,214	+$287,373,853	GUARDANT HEALTH INC, NOVOCURE LTD, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC	13F-HR	14 Nov 2023, 16:36
Q2 2023	81	$3,060,428,640	+$589,173,408	-$680,885,126	-$91,711,718	GUARDANT HEALTH INC, EXACT SCIENCES CORP, NOVOCURE LTD, NANOSTRING TECHNOLOGIES INC, ASCENDIS PHARMA A/S	13F-HR	14 Aug 2023, 16:29
Q1 2023	81	$2,924,706,963	+$463,204,594	-$495,570,711	-$32,366,117	GUARDANT HEALTH INC, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, ALPHATEC HLDGS INC	13F-HR	15 May 2023, 17:18
Q4 2022	88	$2,946,459,579	$0	$0	$0	GUARDANT HEALTH INC, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, EXACT SCIENCES CORP, ALPHATEC HLDGS INC	13F-HR	14 Feb 2023, 16:27